40 results about "Use estrogen" patented technology

This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration. This invention also relates to methods of assessing vaginal health.

The present invention relates to a method of treating or preventing estrogen-suppressed tumours in a mammal, said method comprising the administration of a therapeutically effective amount of an estrogenic component to said mammal, wherein the estrogenic component is selected from the group consisting of: substances represented by the following formula (I)

in which formula R₁, R₂, R₃, R₄, independently are a hydrogen atom, a hydroxyl group or an alkoxy group with 1-5 carbon atoms; precursors capable of liberating a substance according to the aforementioned formula when used in the present method; and mixtures of one or more of the aforementioned substances and/or precursors. The estrogenic component according to the invention is particularly useful in the treatment or prevention of colorectal and prostate cancer and, unlike commonly used estrogens, does not simultaneously enhance the risk of estrogen-stimulated cancers such as breast cancer.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, neurodegenerative diseases or disorders, such as Alzheimer's disease, Parkinson's Disease, multiple sclerosis, stroke, ALS Pick's disease, prion disease and Huntington's disease. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of the diseases and disorders.

A method for preventing or treating a catamenial migrainous disorder in a female subject comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition that is bioadhesive thereto and comprises at least one estrogenic compound in an amount of about 50 μg to about 1000 μg estradiol equivalent per unit dose of the composition. A related method comprises administering to a vulvovaginal surface of the subject a pharmaceutical composition comprising at least one estrogenic compound, wherein upon administration of the composition to the vulvovaginal surface, a decline in serum estradiol concentration during a luteal phase of a menstrual cycle is moderated.

Therapeutic methods of using certain heterocyclic arylidene aryl ether compounds for treating diseases or disorders mediated through modulation of estrogen related receptor alpha are described.

A process for extracting triterpenoid from the dried root of Achyranthes bidentata includes such steps as pulverizing, hot reflux extracting in alcohol, extracting with ethyl acetate 1-4 times, mixing with distilled water, extracting with n-butanol 1-4 times and extracting with water. The liquid extract can be used to treat osteoporosis, especially the osteoporosis of women, with high curative effect.

The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases) and more particularly. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.

The present invention provides that ERRγ is both a breast cancer biomarker and a breast cancer treatment target. A high ERRγ level in breast cancer cells indicates good prognosis. A high level of ERRγ in breast tissue suspected of being cancerous is indicative of breast cancer. Analyzing ERRγ status and optionally along with the status of ERα can help breast cancer patients make treatment choices. Furthermore, breast cancer can be treated by decreasing ERRγ activity in breast cancer cells.

Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.

The present invention relates to a composition for the inhibition or prevention of a bone mineral density reduction, or food and drink for use in such application, comprising isoxanthohumol or an isomerized hop extract as an active ingredient. According to the present invention, a bone mineral density reduction can be inhibited or prevented while avoiding a problem of side effect which may be induced by using an estrogen preparation.

The invention belongs to the field of plant breeding, relates to the field of plant biotechnology breeding, and particularly relates to a method for creating a phenotypic variation transgenic plant byutilizing a methyltransferase gene. According to the method, an agrobacterium-mediated method is used for introducing a chemical induction promoter and the arabidopsis DNA methyltransferase gene AtMET1 into an 84K poplar genome to obtain an AtMET1 84K poplar plant, a sterile in-vitro leaf AtMET1 of the transgenic plant is induced to express for 3 hours, 12 hours and 24 hours by using estrogen, and then the leaf is induced to regenerate to obtain the phenotypic variant plant. According to the research, the chemical induction promoter is used for artificially promoting exogenous gene expression, phenotypic variation germplasm is created, and plant breeding resources are enriched.

The present invention relates to treatment of neurological diseases such as multiple sclerosis (MS) and Alzheimer's disease, using an estrogen receptor beta (ERβ) ligand in combination with a standard, anti-inflammatory agent.

The invention relates to a building method of a non-human primate dysmenorrheal model and a measuring principle of non-human primate dysmenorrheal pains. Combined induction of estrogen and oxytocin isutilized to build the non-human primate dysmenorrheal pain model, and a measurement device is utilized to measure the pains. When the device measures the pains, a medium loading unit is connected with a flexible expansion unit through a communication pipe, after the flexible expansion unit is put into the vagina of a primate, mediums are loaded according to a preset procedure to expand the expansion unit, a measuring monitoring unit is connected with the primate and a medium loading controlling unit separately, and by detecting the reaction of the primate to the pains and feeding the reactionback to the medium loading controlling unit, and recording loading data at the same time, the degree of the dysmenorrheal pains is quantitatively measured. As is shown by cases, the measuring methodis high in sensitivity and repeatability. The dysmenorrheal model and the measuring principle and method of the non-human primate dysmenorrheal pains have a wide application range in the relevant field of scientific research, teaching, products and technological development and the like, and can also provide experimental estimation for the development of new drugs for the dysmenorrheal pains.

A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 mug of 17alpha-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.

Compositions and methods for reducing the body weight of a mammal are disclosed. The invention is directed to methods for reducing the body weight in a mammal comprising administering therapeutically effective amounts of a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a serotonin reuptake-inhibiting compound. Furthermore the invention is directed to compositions comprising a fatty-acid ester of an estrogen or estrogen derivative and a fatty-acid, and a serotonin reuptake-inhibiting compound.

Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof.